Daily Low-Dose Aspirin Shows No Benefit for Healthy Lifespan in Older Adults
A major NIH-backed study finds that daily low-dose aspirin does not extend healthy lifespan in older people, challenging a long-held preventive health belief.
Summary
For decades, many older adults took a daily low-dose aspirin hoping to stay healthier longer. A large NIH-supported study has now found that this practice provides no meaningful benefit for extending healthy lifespan in older people without existing cardiovascular disease. Participants who took aspirin daily did not live more years free of disability, dementia, or major illness compared to those who took a placebo. These findings build on earlier work showing aspirin also failed to reduce heart attack and stroke risk in healthy older populations, while carrying real bleeding risks. The results suggest that routine aspirin use for longevity purposes in otherwise healthy older adults is not supported by evidence and may warrant a conversation with a physician about stopping.
Detailed Summary
Low-dose aspirin has long been a staple of preventive medicine, with millions of older adults taking it daily in the belief it would help them live longer, healthier lives. That assumption is now under serious scrutiny following a major NIH-supported study reporting that daily aspirin has no measurable effect on healthy lifespan in older people.
The research examined whether aspirin could extend the period of life spent free from serious disease, disability, or cognitive decline — what researchers call 'healthy lifespan' or healthspan. This is a clinically meaningful endpoint because living longer only matters if those additional years are spent in good health.
The study found no significant difference between aspirin and placebo groups in the number of healthy years lived. Participants taking aspirin did not experience fewer years burdened by major illness, dementia, or functional impairment. This null result held across the older adult population studied.
These findings align with and extend prior results from the ASPREE trial, which previously showed that aspirin did not reduce cardiovascular events in healthy older adults and was associated with increased risk of serious bleeding, including gastrointestinal and intracranial hemorrhage. Together, the evidence paints a consistent picture: the risk-benefit calculus for aspirin in primary prevention among older adults does not favor routine use.
The implications for clinical practice are significant. Physicians and patients who have maintained aspirin use for longevity or general preventive purposes should reassess this habit in light of the accumulated evidence. The study reinforces current American Heart Association and American College of Cardiology guidance recommending against initiating aspirin therapy for primary prevention in adults over 60. Caveats include that the full study details were not available for this summary, which is based on the press release abstract only.
Key Findings
- Daily low-dose aspirin did not extend healthy lifespan in older adults compared to placebo.
- No reduction was observed in years spent free from disability, dementia, or major illness.
- Findings reinforce existing guidance against aspirin for primary prevention in adults over 60.
- Prior ASPREE data showed aspirin also failed to cut cardiovascular events while raising bleeding risk.
- Older adults taking aspirin for longevity purposes should discuss stopping with their physician.
Methodology
The study appears to be an analysis from the ASPREE (ASPirin in Reducing Events in the Elderly) trial or a related NIH-supported cohort, examining healthy lifespan as a composite endpoint. It involved older adults without existing cardiovascular indications for aspirin, randomized to low-dose aspirin or placebo. Full methodological details were not available as this summary is based on a press release.
Study Limitations
This summary is based on the press release abstract only; the full study methodology, sample size, follow-up duration, and statistical details were not available for review. The precise definition of 'healthy lifespan' used as the primary endpoint could not be verified. Findings may not generalize to older adults who already have established cardiovascular disease or other specific indications for aspirin.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.